ES2163394T3 - Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16. - Google Patents

Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16.

Info

Publication number
ES2163394T3
ES2163394T3 ES92110430T ES92110430T ES2163394T3 ES 2163394 T3 ES2163394 T3 ES 2163394T3 ES 92110430 T ES92110430 T ES 92110430T ES 92110430 T ES92110430 T ES 92110430T ES 2163394 T3 ES2163394 T3 ES 2163394T3
Authority
ES
Spain
Prior art keywords
proteins
serrereactive
hpv16
seroactive
regions situated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92110430T
Other languages
English (en)
Inventor
Martin Muller
Lutz Gissmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Dade Behring Marburg GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dade Behring Marburg GmbH filed Critical Dade Behring Marburg GmbH
Application granted granted Critical
Publication of ES2163394T3 publication Critical patent/ES2163394T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A PROTEINAS E1 Y E2 DE CAMPO SEROACTIVO DE LOS VIRUS PAPILOMAS HUMANOS (HPV) 16. ADEMAS LA INVENCION SE REFIERE A UNA VACUNA, QUE CONTIENE TAL PEPTIDO, QUE ABARCA LOS CAMPOS SEROACTIVOS. LA INVENCION ABARCA ASIMISMO COMPOSICIONES PARA MOTIVO DE DIAGNOSTICO, QUE CONTIENEN PEPTIDOS CON EL CAMPO SEROACTIVO.
ES92110430T 1991-07-18 1992-06-20 Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16. Expired - Lifetime ES2163394T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4123760A DE4123760C2 (de) 1991-07-18 1991-07-18 Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2

Publications (1)

Publication Number Publication Date
ES2163394T3 true ES2163394T3 (es) 2002-02-01

Family

ID=6436409

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92110430T Expired - Lifetime ES2163394T3 (es) 1991-07-18 1992-06-20 Regiones serorreactivas situadas en las proteinas e1 y e2 de hpv16.

Country Status (10)

Country Link
US (5) US5601973A (es)
EP (2) EP1136500A3 (es)
JP (2) JPH0867696A (es)
AT (1) ATE206434T1 (es)
AU (1) AU668094B2 (es)
CA (1) CA2074153C (es)
DE (2) DE4123760C2 (es)
DK (1) DK0523395T3 (es)
ES (1) ES2163394T3 (es)
PT (1) PT523395E (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69938242T2 (de) * 1998-07-21 2009-04-09 Boehringer Ingelheim (Canada) Ltd., Laval Regionen des papillomavirus-e1-helikase beteiligt an e1 oligomerisierung
GB9916363D0 (en) * 1999-07-13 1999-09-15 Univ Bristol Methods of suppressing cell growth
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
ATE346947T1 (de) * 2000-07-21 2006-12-15 Glaxo Group Ltd Kodon-optimierte papillomavirussequenzen
ES2519043T3 (es) 2000-12-08 2014-11-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US7027923B2 (en) * 2003-12-12 2006-04-11 Schlumberger Technology Corporation Method for determining sonde error for an induction or propagation tool with transverse or triaxial arrays
US20090028874A1 (en) * 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
CA2605749C (en) 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
KR101811965B1 (ko) 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
CN102449479B (zh) 2009-05-07 2015-11-25 安科健康公司 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
JP7038064B2 (ja) 2016-04-18 2022-03-17 セルデックス セラピューティクス インコーポレイテッド ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3475706B1 (en) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
US12391746B2 (en) 2018-02-20 2025-08-19 Emory University HPV proteins, antibodies, and uses in managing abnormal epithelial cell growth
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
EP3775238A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
SG11202101204TA (en) 2018-08-09 2021-03-30 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
MX2021002574A (es) 2018-09-11 2021-06-08 Juno Therapeutics Inc Metodos para el analisis por espectrometria de masas de composiciones de celulas modificadas.
AU2020265741A1 (en) 2019-05-01 2021-11-25 Editas Medicine, Inc. Cells expressing a recombinant receptor from a modified TGFBR2 Locus, related polynucleotides and methods
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
CN119529069B (zh) * 2025-01-22 2025-07-01 成都迈科康生物科技有限公司 一种抗hpv16和/或hpv18型e2蛋白的抗体、抗体偶联物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
JPH063211B2 (ja) * 1989-03-01 1994-01-12 テイエチケー株式会社 直線摺動用ベアリング及び直線摺動用ベアリングの組付け方法
PT97073A (pt) * 1990-03-20 1991-10-31 Behringwerke Ag Processo para a preparacao de epitopos soro-reactivos de proteinas de papillomavirus 16 humano (hpv)
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay

Also Published As

Publication number Publication date
DE4123760A1 (de) 1993-01-21
US6221577B1 (en) 2001-04-24
JP2003327598A (ja) 2003-11-19
DE4123760C2 (de) 2000-01-20
EP1136500A3 (de) 2004-03-24
US20010034021A1 (en) 2001-10-25
AU668094B2 (en) 1996-04-26
CA2074153C (en) 2003-10-07
US6531127B2 (en) 2003-03-11
US20040152074A1 (en) 2004-08-05
CA2074153A1 (en) 1993-01-19
PT523395E (pt) 2002-03-28
US20030147915A1 (en) 2003-08-07
ATE206434T1 (de) 2001-10-15
JPH0867696A (ja) 1996-03-12
EP0523395A3 (es) 1994-12-14
EP0523395B1 (de) 2001-10-04
EP1136500A2 (de) 2001-09-26
AU2042992A (en) 1993-01-21
DK0523395T3 (da) 2002-02-04
EP0523395A2 (de) 1993-01-20
DE59209921D1 (de) 2001-11-08
US6723317B2 (en) 2004-04-20
US5601973A (en) 1997-02-11

Similar Documents

Publication Publication Date Title
EA200400241A1 (ru) Направленные к мишени мультимерные контрастные вещества, основанные на пептидах
SE9004010D0 (sv) Viralt medel
EA199901031A1 (ru) Производные бензимидазола
AR006999A1 (es) Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende.
ES2169043T3 (es) Peptidos del papilomavirus humano aplicable en las composiciones para inducir una reaccion de los linfocitos t en el hombre.
EA199700215A1 (ru) Защита от вирусных инфекций путем колонизации слизистых оболочек генетически модифицированными бактериями
CA2074153A1 (en) Seroreactive regions on hpv 16 proteins e1 and e2
ES2101077T3 (es) Procedimiento para la inactivacion de priones.
ES2143558T3 (es) Agentes policiclicos antiparasitarios, procedimiento y cepa para su preparacion y su uso.
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
ES2045475T3 (es) Rna del genoma del virus de la hepatitis no-a, no-b, cdna y proteina del antigeno del virus.
ATE236262T1 (de) Rekombinanter schweinepocken-virus
ES2075040T3 (es) 2',3'-dideoxi-2',2'-difluoronucleosidos.
ES2071815T3 (es) Analogos de delecion de los peptidos conocidos como magaininas.
ES2145000T3 (es) Virus recombinante del avipox.
MX9703570A (es) Proteinas de virus de papiloma purificadas.
ATE189818T1 (de) Papillomavirusuntereinheit-impfstoff
BR0211186A (pt) peptìdeos e uso dos mesmos no escurecimento da pele
ES2153861T3 (es) Mejoras relativas a composiciones antibacterianas.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ES2185417T3 (es) Excipientes para usar en formulaciones farmaceuticas de virus adeno-asociados, y formulaciones farmaceuticas producidas con ellos.
ES2058100T3 (es) Vacuna combinada.
AR004497A1 (es) Un análogo hexapéptido cíclico de somatostatina, procedimiento para prepararlos y las composiciones farmacéuticas que los contienen y el uso de dicho hexapéptido para la preparación de una composición farmacéutica.
ATE201693T1 (de) Hämoregulierende peptide
ES2057579T3 (es) Peptidos e1 y c de rubeola.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 523395

Country of ref document: ES